IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0213752.html
   My bibliography  Save this article

Accounting for long-term manifestations of Cryptosporidium spp infection in burden of disease and cost-of-illness estimations, the Netherlands (2013–2017)

Author

Listed:
  • Susana Monge
  • Roan Pijnacker
  • Wilfrid van Pelt
  • Eelco Franz
  • Laetitia M Kortbeek
  • Marie-Josée J Mangen

Abstract

Background: Burden of disease (BoD) estimations are increasingly used to prioritize public health interventions. Previous Cryptosporidium BoD models accounted only for acute episodes, while there is increasing evidence of long-term manifestations. Our objective was to update Cryptosporidium BoD and cost-of-illness (COI) models and to estimate BoD and COI for the Netherlands in years 2013–2017. Methods: We performed a scoping literature review and drew an outcome tree including long-term manifestations for which sufficient evidence was found, such as recurrent diarrhea and joint pain. We chose the Disability-Adjusted Life Year (DALY) metric to synthesize years of life lost due mortality (YLLs) and years lived with disability due to non-fatal outcomes (YLDs). For the costs, we adopted a societal perspective accounting for direct healthcare costs, patient costs and productivity losses. Uncertainty was managed using Latin Hypercube sampling (30,000 iterations). Results: In the Netherlands in 2017, we estimated 50,000 Cryptosporidium cases (95% uncertainty interval (UI): 15,000–102,000), 7,000 GP visits, 300 hospitalizations and 3 deaths, resulting in 137 DALYs (95%UI: 54–255) and €19.2 million COI (95%UI: €7.2 million– €36.2 million). Estimates were highest for 2016 (218 DALYs and €31.1 million in COI), and lowest in 2013 (100 DALYs and €13.8 million in COI). Most of the BoD was attributable to YLD (≈80% of DALYs). The most important cost was productivity losses (≈90% of total COI). Long-term manifestations, including recurring diarrhea and joint pain, accounted for 9% of the total DALYs and 7% of the total COI. Conclusion: Current evidence supports the inclusion of long-term manifestations in Cryptosporidium models, which contribute close to 10% of the total DALYs and costs. This may be an underestimation, as we were conservative in our assumptions. Cryptosporidium should be considered a priority organism with respect to public health surveillance, even in industrialized countries with high hygiene standards.

Suggested Citation

  • Susana Monge & Roan Pijnacker & Wilfrid van Pelt & Eelco Franz & Laetitia M Kortbeek & Marie-Josée J Mangen, 2019. "Accounting for long-term manifestations of Cryptosporidium spp infection in burden of disease and cost-of-illness estimations, the Netherlands (2013–2017)," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-16, March.
    • Handle: RePEc:plo:pone00:0213752
    DOI: 10.1371/journal.pone.0213752
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0213752
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0213752&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0213752?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Koopmanschap, Marc A. & Rutten, Frans F. H. & van Ineveld, B. Martin & van Roijen, Leona, 1995. "The friction cost method for measuring indirect costs of disease," Journal of Health Economics, Elsevier, vol. 14(2), pages 171-189, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Iris Arends & Ute Bültmann & Willem van Rhenen & Henk Groen & Jac J L van der Klink, 2013. "Economic Evaluation of a Problem Solving Intervention to Prevent Recurrent Sickness Absence in Workers with Common Mental Disorders," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-1, August.
    2. Anne Tiainen & Clas Rehnberg, 2010. "The Economic Burden of Psychiatric Disorders in Sweden," International Journal of Social Psychiatry, , vol. 56(5), pages 515-526, September.
    3. Tilling, C & Krol, M & Tsuchiya, A & Brazier, J & van Exel, J & Brouwer, W, 2009. "The impact of losses in income due to ill health: does the EQ-5D reflect lost earnings?," MPRA Paper 29837, University Library of Munich, Germany.
    4. Md Zahid Hasan & Gazi Golam Mehdi & Khadija Islam Tisha & Md Golam Rabbani & Mohammad Wahid Ahmed & Subrata Paul & Ziaul Islam & Shehrin Shaila Mahmood, 2025. "Costs of outpatient services at selected primary healthcare centers in Bangladesh: A cross-sectional study," PLOS ONE, Public Library of Science, vol. 20(1), pages 1-15, January.
    5. Hanly, Paul & Ortega Ortega, Marta & Pearce, Alison & Soerjomataram, Isabelle & Sharp, Linda, 2020. "Advances in the methodological approach to friction period estimation: A European perspective," Social Science & Medicine, Elsevier, vol. 264(C).
    6. Siri Fauli & Geir Thue, 2008. "Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 221-228, August.
    7. Jakob, 2025. "Absenteeism and Firm Performance: Evidence from Retail," Discussion Paper Series of the Max Planck Institute for Research on Collective Goods 2025_02, Max Planck Institute for Research on Collective Goods.
    8. Paul Hanly & Rebecca Maguire & Frances Drummond & Linda Sharp, 2019. "Variation in the methodological approach to productivity cost valuation: the case of prostate cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(9), pages 1399-1408, December.
    9. Jonathan Karnon & Jill Carlton & Carolyn Czoski-Murray & Kevin Smith, 2009. "Informing disinvestment through cost-effectiveness modelling," Applied Health Economics and Health Policy, Springer, vol. 7(1), pages 1-9, March.
    10. Thomas DeLeire & Willard Manning, 2004. "Labor market costs of illness: prevalence matters," Health Economics, John Wiley & Sons, Ltd., vol. 13(3), pages 239-250, March.
    11. Tobias Effertz & Susanne Engel & Frank Verheyen & Roland Linder, 2016. "The costs and consequences of obesity in Germany: a new approach from a prevalence and life-cycle perspective," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1141-1158, December.
    12. Allison Larg & John Moss, 2011. "Cost-of-Illness Studies," PharmacoEconomics, Springer, vol. 29(8), pages 653-671, August.
    13. Klose, Thomas, 1999. "The contingent valuation method in health care," Health Policy, Elsevier, vol. 47(2), pages 97-123, May.
    14. Annie Hawton & James Shearer & Elizabeth Goodwin & Colin Green, 2013. "Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 331-341, August.
    15. Foster, Nicola & Vassall, Anna & Cleary, Susan & Cunnama, Lucy & Churchyard, Gavin & Sinanovic, Edina, 2015. "The economic burden of TB diagnosis and treatment in South Africa," Social Science & Medicine, Elsevier, vol. 130(C), pages 42-50.
    16. Antoine Bailly & Et Carole Chichignoud, 2006. "Risques Et Santé/Riesgos Y Salud," Estudios de Economia Aplicada, Estudios de Economia Aplicada, vol. 24, pages 865-874, Diciembre.
    17. Hansen, Kristian S. & Moreno-Ternero, Juan D. & Østerdal, Lars P., 2024. "Quality- and productivity-adjusted life years: From QALYs to PALYs and beyond," Journal of Health Economics, Elsevier, vol. 95(C).
    18. Orsolya Balogh & Valentin Brodszky & László Gulácsi & Emese Herédi & Krisztina Herszényi & Hajnalka Jókai & Sarolta Kárpáti & Petra Baji & Éva Remenyik & Andrea Szegedi & Péter Holló, 2014. "Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 101-109, May.
    19. Marie Kruse & Jan Sørensen & Dorte Gyrd-Hansen, 2012. "Future costs in cost-effectiveness analysis: an empirical assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 63-70, February.
    20. James Shearer & Paul McCrone & Renee Romeo, 2016. "Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches," PharmacoEconomics, Springer, vol. 34(7), pages 651-664, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0213752. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.